Evidence map›Paper›PMID 31834934›Full record

ArticleBlood advances2019

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.

Ferdows Atiq, Lisette M Schütte, Agnes E M Looijen, Johan Boender, Marjon H Cnossen, Jeroen Eikenboom, Moniek P M de Maat, Marieke J H A Kruip, Frank W G Leebeek

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ferdows AtiqDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Lisette M SchütteDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Agnes E M LooijenDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Johan BoenderDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marjon H CnossenDepartment of Pediatric Hematology, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands; and.
Jeroen EikenboomDivision of Thrombosis and Hemostasis, Department of Internal Medicine and.
Moniek P M de MaatDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marieke J H A KruipDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Frank W G LeebeekDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bleeding phenotype of patients with type 1 von Willebrand disease (VWD) is very heterogeneous. We hypothesized that this heterogeneity may partly be explained by variability in response of von Willebrand factor (VWF) and factor VIII (FVIII) levels to stress during hemostatic challenges. We therefore investigated whether VWF and FVIII levels after administration of desmopressin, which mimic in vivo hemostatic response during hemostatic challenges, explain the heterogeneity in bleeding phenotype of patients with type 1 VWD. We performed a retrospective cohort study in 122 patients with type 1 VWD. All patients received a test dose of desmopressin shortly after diagnosis. Patients' mean age was 47 ± 14 years, and the mean Tosetto bleeding score was 10 ± 7. Higher FVIII activity during the complete time course after desmopressin administration (1, 3, and 5-6 hours), and higher VWF and FVIII levels combined at 3 hours after desmopressin administration, were associated with a lower bleeding score: β = -0.9 (-1.7; -0.1) and β = -1.2 (-1.9; -0.5), respectively, adjusted for age, sex, body mass index (BMI), and comorbidities. Patients with FVIII activity in the highest quartile 3 hours after desmopressin administration had a much lower bleeding score compared with patients in the other 3 quartiles (β = -5.1 [-8.2; -2.0]) and also had a lower chance of an abnormal bleeding score (odds ratio = 0.2 [0.1-0.5]), both adjusted for age, sex, BMI, and comorbidities. In conclusion, VWF and FVIII levels after desmopressin administration, which mimic hemostatic response to hemostatic challenges, are associated with the bleeding phenotype of patients with type 1 VWD. This may partly explain the variability in bleeding phenotype of these patients.

Indexed as

Factor VIIIvon Willebrand FactorAdultBiomarkersBlood CoagulationDeamino Arginine VasopressinFemaleHemorrhageHemostaticsHumansMaleMiddle AgedPhenotypeRetrospective StudiesTime FactorsTreatment OutcomeBiomarkersDeamino Arginine VasopressinFactor VIIIHemostaticsvon Willebrand Factor

Identifiers

PMID31834934
PMCPMC6929395
OpenAlexW2995206333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.